Physician profile
Madhusmita Misra
NPI 1043291107
$4,160.72
in general payments reported to CMS, 2019-2025
7 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $2,130 · 2024: $1,680 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,960 · Food and Beverage: $70.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,960.00 |
| Food and Beverage | $70.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,960.00 | 2024-2025 | |
| Abbvie INC. | $1,350.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $780.00 | 2020 | |
| Biomarin Pharmaceutical INC. | $70.72 | 2025 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhusmita Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.